Important note

This AI stock analysis for McKesson is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

McKesson - AI Stock Analysis

Analysis generated September 27, 2024

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology, specialty care, and healthcare information technology. The company distributes pharmaceuticals at a national network of distribution centers and provides healthcare management tools and scalable solutions to reduce costs, improve operational efficiency and enhance the quality of care. With a robust history of innovation and leadership, McKesson plays a pivotal role in the healthcare industry.

Fundamental Analysis

In the last quarter, McKesson's revenue stood at $79.3 billion, marking an increase of 3.90% compared to the prior quarter and a 6.50% increase year-over-year. This indicates steady growth in the company’s sales and market penetration.

The net income for the last quarter was $915 million, showcasing a considerable increase of 15.68% from the previous quarter but a decrease of 4.49% compared to the same quarter last year. While quarter-on-quarter growth is a healthy sign, the year-over-year decline in net income raises some concerns about profitability trends.

EBITDA for the last quarter at $1.18 billion decreased by 29.10% from the previous quarter, but there was a year-over-year increase of 1.38%. The quarterly decline in EBITDA is alarming and warrants further scrutiny into operational efficiencies and cost management strategies.

McKesson's current Price-to-Earnings (P/E) ratio is 21.41. This suggests that the stock is fairly valued, with the P/E ratio not signaling any imminent overvaluation or undervaluation.

However, the recent insider selling activity could be a bearish indicator, as it might reflect insiders' lack of confidence in the company’s short-term stock performance.

Technical Analysis

Today's stock price is $486.84, down 11.49% from a month ago, which may be a short-term concern. However, on a yearly basis, the stock has increased by 10.67%, indicating a positive long-term trend.

The recent price movements indicate a bearish trend. The SMA10 stands at 497.43, down from the previous 500.14, suggesting potential downward price movement in the near future.

The Relative Strength Index (RSI) is at 76.4, indicating the stock is potentially overbought, which is another bearish signal.

Alternative Data Analysis

In terms of job postings and employee sentiment, McKesson has 424 open positions, down by 15% in the last few months. This reduction could indicate efforts to cut costs or improve margins, which is not a great indicator for growth prospects.

Employee sentiment towards the company is neutral, adding to the mixed signals about the internal outlook.

Looking at customer acquisition, McKesson's website saw an estimated 3.1 million visitors, up by 14% in recent months. This is a positive trend, suggesting potential growth in customer base.

Customer engagement metrics such as social media following are stable, with no significant changes: 10,000 followers on Instagram and 22,000 followers on Twitter.

AltIndex's AI score for McKesson is 46, which stands as a hold signal.

Conclusion and Recommendation

McKesson presents a robust company with strong revenue and net income growth signals, although recent EBITDA declines and mixed insider activity introduce some risk. Technically, the stock shows bearish short-term trends but coupled with a positive long-term trajectory. Alternative data also reflects a mixed outlook given reduced job postings but increased web traffic.

Taking all factors into account, including the AI score of 46 indicating a hold, it would be prudent for investors to maintain a hold position on McKesson stock. While there are positive indicators of growth, several red flags and the current bearish trend suggest caution until there is clearer positive momentum.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.